Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (November 2024)

63 slides from Corbus Pharmaceuticals's investor presentation, Nov 4, 2024

  1. Slide 1: Connecting Innovation to Purpose

    Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation November 4, 2024 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, prod

  3. Slide 3: Investment Summary

    Investment Summary $147M Cash, cash equivalents and investments as of June 30, 2024. Approximately 11.5M Common Shares Outstanding (~12.5M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for tre

  4. Slide 4: A Diversified Pipeline with Differentiated Clinical Risk Profiles

    Therapy Disease Indication Sponsor Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones Next-Generation Nectin-4 targeting ADC CRB-701 Next-generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Multiple Cohorts Expanding Corbus (US + Europe) Enrollment for Dose Escalation Stage Co

  5. Slide 5: CRB-701 Next Generation Nectin-4 Targeting ADC

    CRB-701 Next Generation Nectin-4 Targeting ADC

  6. Slide 6: PADCEV Projected to Reach Up to ~$5B in Global Sales

    PADCEV® Projected to Reach Up to ~$5B in Global Sales by 2028 Sources: 1. SGEN press release, October 2023, 2. Evaluate Pharma PADCEV® Global Projected Revenues in UC/Bladder2 $5B Latest Padcev® Q3 revenues 1 22nd October 2023 2 ® Groundbreaking EV-302 Trial Significantly Extends Overall Survival an

  7. Slide 7: Does Tolerability for PADCEV Impact Clinical Adoption?

    Does Tolerability for PADCEV® Impact Clinical Adoption? Source(s): PADCEV® Prescribing Information as of Apr 2023. Duration of Response ~5 months 47% Rate of Serious Adverse Events (SAEs) 61% Dose Interruptions 34% Dose Reductions 17% Dose Discontinuations Revised: 4/2023 PADCEV® Prescribing Informa

  8. Slide 8: PADCEV is Associated with Skin Toxicities and Peripheral Neuropathy

    PADCEV® is Associated with Skin Toxicities and Peripheral Neuropathy Source(s): 1. PADCEV® Prescribing Information Dec 2023. 2.Rosenberg et al. 2020 Adverse Events (% of Patients) ® A Black Box Warning1 Greater than 25% of PADCEV® discontinuations are linked to peripheral neuropathy 2 PADCEV® + Keyt

  9. Slide 9: Is the 2nd Generation Seagen Linker the Cause?

    ADC drug TAA Average DAR Skin Rash Peripheral Neuropathy PADCEV® Enfortumab vedotin Nectin-4 3.8 Adcetris® Brentuximab vedotin CD30 4 Tivdak® Tisotumab vedotin TF 4 Polivy® Polatuzumab vedotin CD79B 3.5 Aidixi® Disitamab vedotin HER2 4 Is the 2nd Generation Seagen® Linker the Cause? Padcev® Val-Cit

  10. Slide 10: PADCEV Requires Frequent Dosing and Real-world Usage Differs from Label

    6 months of therapy = ~ 54 hours of total clinic time / patient Real-world use, dose intensity, and adherence to PADCEV® PADCEV® Requires Frequent Dosing and Real-world Usage Differs from Label Source(s): 1. PADCEV® Prescribing Information as of Dec 2019, 2. Redacted from Tsingas et al., ASCO 2023 M

  11. Slide 11: Designing a Nectin-4 ADC Intended to Address PADCEV Unmet Needs

    Nectin-4 targeting ADC for treatment of solid tumors Extend ADC half-life  Reduce dosing frequency Lower DAR + longer half-life  Dose higher than PADCEV® Compliance Efficacy Toxicity Designing a Nectin-4 ADC Intended to Address PADCEV® Unmet Needs

  12. Slide 12: CRB-701: Next Generation Site-specific Nectin-4 Targeting ADC

    CRB-701: Next Generation Site-specific Nectin-4 Targeting ADC MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity. CDC = complement dependent cytotoxicity Source(s): Modified image from Corbus data on file; Corbus data on file Novel Nectin-4 Antibody ADCC + CDC functionali

  13. Slide 13: CRB-701: One Dose Every 3 Weeks Offers Advantages

    CRB-701: One Dose Every 21 Days Offers Advantages Over More Frequent Dosing Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2019 PADCEV® CRB-701 Clinical Cycle Comparison Patient / Physician Convenience Combination Flexibility

  14. Slide 14: ASCO 2024 Update: Phase 1 Dose Escalation Study (China)

    ASCO 2024 Update: Phase 1 Dose Escalation Study (China) KEY ELIGIBILITY Age ≥ 18 years Advanced urothelial carcinoma or Nectin-4 positive Advanced solid tumors ECOG 0-1 Adequate organ function No uncontrolled diabetes No active CNS metastasis ESCALATION DESIGN Bayesian Optimal Interval (BOIN) design

  15. Slide 15: ASCO 2024 Update: Demographics & Key Characteristics

    ASCO 2024 Update: Demographics & Key Characteristics Characteristic Value Median age (range) 55 (35, 76) Sex (M/F) 29.7%, 70.3% ECOG PS 0,1, missing 8.1%, 89.2%, 2.7% Weight in Kg mean (range) 59.01 (36.0, 84.9) Prior therapies median (range) 4.0 (0,10) Creatinine clearance <60μ mol/L 29.7% Visceral

  16. Slide 16: ASCO 2024 Update: Safety and Dose Modifications

    ASCO 2024 Update: Safety and Dose Modifications Dose Modifications n Discontinuations 0 Reductions 0 Interruptions 1 CRB-701 continues to be well tolerated with mainly grade 1 or 2 AEs Still no DLTs or Grade 4 or 5 AEs observed to date including in the 4.5 mg/Kg cohort No additional grade 3 treatmen

  17. Slide 17: ASCO 2024 Update: TEAEs of Special Interest

    ASCO 2024 Update: TEAEs of Special Interest (<20% incidence) AE of special interest Grade Dose (n out of 37) Notes Skin rash 3 2.7 mg/Kg (n=1) Resolved after 8 days (no dose change) Skin rash 2 3.6mg/kg (n=1) Resolved after 5 weeks (no dose change) Skin rash 1 3.6 mg/kg (n=1) Resolved after 19 days

  18. Slide 18: ASCO 2024 Update: Pharmacokinetics

    ASCO 2024 Update: Pharmacokinetics Continuing to indicate differentiation from PADCEV® Delivering higher amounts of ADC at the higher doses explored Consistently less free MMAE levels across all doses tested to date 21 Day PK Comparison %ADC %Free MMAE Cmax AUC0-21d Cmax AUC0-21d Enfortumab vedotin

  19. Slide 19: Favorable Emerging Safety Profile vs. Nectin-4 ADC Competitors

    Favorable Emerging Safety Profile vs. Nectin-4 ADC Competitors 1 Rosenberg, et al., JCO, 2020 Apr 1; 38(10): 1041–1049, 2. NDA/BLA Multidisciplinary Review and Evaluation BLA 761137 PADCEV™ (enfortumab vedotin-ievx), 3.Torras, O. Reig, et al. "652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve

  20. Slide 20: ASCO 2024 Update: Dose Escalation Disease Responses

    ASCO 2024 Update: Phase 1 Dose Escalation Disease Responses Two of seven PRs are ongoing and unconfirmed. All of the previous (January ASCO GU data) PRs were confirmed.

  21. Slide 21: ASCO 2024 Update: Disease Response-mUC & Cervical

    ASCO 2024 Update: Disease Response-mUC & Cervical ≥ 1.2 mg/Kg ORR: 43% (3 of 7 at 2.6mg and 3.6mg/Kg) DCR: 86% ORR: 44% (4 of 9 at 3.6mg/Kg) DCR: 78% % Change by RECIST criteria Dose mg/kg NECTIN-4 3.6 3.6 2 .7 3.6 4.5 3.6 2.7 3.6 1.2 205 0 105 n.a. 271 220 190 293 175 3.6 3.6 3.6 1 .8 3.6 3.6 3.6 8

  22. Slide 22: ASCO 2024 Update: Swimmer Plots

    ASCO 2024 Update: Swimmer Plots

  23. Slide 23: ASCO 2024 Update: Phase 1 Summary Data

    ASCO 2024 Update: Phase 1 Summary Data Objective Response Rate in mUC at doses ≥ 1.2 mg/KG 44%: 4 out of 9 patients with PR’s (1 unconfirmed, DCR-78%) Objective Response Rate in Cervical at doses≥ 1.2mg/KG 43%: 3 out of 9 patients with PR’s (1 unconfirmed, DCR-86%) Dose for first observed SD 0.2 mg/

  24. Slide 24: CRB-701: A Differentiated Clinical Development Approach to Competitors

    CRB-701: A Differentiated Clinical Development Approach to Competitors Proprietary insights are driving indication selection for CRB-701 New reality of PADCEV® + Keytruda® 1L therapy Under-served niche mUC populations remain and are attractive targets Emerging clinical data from current dose escalat

  25. Slide 25: CRB-701-01 Study Design (Corbus)

    CRB-701-01 Study Design (Corbus) Dose escalation (Enrollment complete) Project Optimus (dose optimization) Dose expansion at RP2D Randomized to 2 doses of CRB-701 monotherapy Randomized to 2 doses of CRB-701 + CPI 1.8 mg/Kg 2.7 mg/Kg 3.6 mg/Kg 4.5 mg/Kg Bladder cancer niche population(s) Non-UC tumo

  26. Slide 26: Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC

    Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC References: 1. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.6017 2. Efficacy and safety of 9MW2821, an antibody-drug conjugate targeting Nectin-4, monotherapy in patients with recurrent or metastatic cervical cancer: A mult

  27. Slide 27: CRB-701 Milestones

    ASCO-2024 Q4-2024 Expected Q1-2025 Expected Milestones Q1-2024 First patient dosed in U.S. dose escalation study Clinical data update on China dose escalation study Enrollment complete U.S. dose escalation study Present U.S. dose escalation data

  28. Slide 28: Competitive Landscape in Cervical Cancer

    Competitive Landscape in Cervical Cancer Tivdak innovaTV-301(2) N=502 Median prior Tx=2 Tivdak initial approval(1) N=101 Median prior Tx=1 Mabwell (3) N=53 Cervical N=240 safety CRB-701 N=37 ORR 17.8% (TV) vs 5.2% (Chemo) (TV: CR 2.4%, PR 15.4%) 23.8% CR 7% PR17% 35.8% (cORR30.2%) Around 40-45% Ocul

  29. Slide 29: Cervical Cancer: Commercial Opportunity for CRB-701

    Cervical Cancer: Commercial Opportunity for CRB-701 14,000 new cervical cases in U.S. annually with 4,000 deaths1 Incidence in U.S. is still growing despite effective HPV vaccination due to: Low HPV screening rates in Asian and Hispanic women, lower vaccination in rural areas and lack of access to i

  30. Slide 30: CRB-701: Summary

    CRB-701: Summary Emerging clinical safety appears differentiated to PADCEV® Clinical activity seen in mUC and cervical cancer patients 3rd generation ADC with improved linker stability, reduces MMAE in circulation

  31. Slide 31: CRB-913 Oral CB1 Inverse Agonist for Obesity

    CRB-913 Oral cannabinoid Type-1 inverse agonist for superior incretin therapy in obesity

  32. Slide 32: CB1 is a Well-Understood Receptor in Metabolism

    Source(s): Targeting the endocannabinoid system in diabesity: Fact or fiction?, Drug Discovery Today, Deeba et al. Mar 2021. CB1 is a Well-Understood Receptor in Metabolism >9K papers in PubMed on CB1 and metabolism

  33. Slide 33: Next-Generation CB1 Inverse Agonists are Peripherally Restricted

    Monlunabant CRB-913 Next-Generation CB1 Inverse Agonists are Peripherally Restricted Rimonabant Otenabant Ibipinabant Taranabant Source(s): Cinar et al 2020 First-generation (2000-2007) Next-generation (2020 onwards) Designed to target the brain with high BBB penetration  FDA rejection due to safet

  34. Slide 34: Clinical efficacy of monlunabant vs rimonabant

    Clinical efficacy of monlunabant vs rimonabant: what do we know? * Sources: RIO North America (Pi Snuyer et al 2006) ** Novo PR Sept 2024 *** Crater et al 2023 N =1214* N =60** N = 20*** Placebo-adjusted weight loss cross-trial comparison N =1219* -5.7% -1.7% -5.8% -3.8%

  35. Slide 35: CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist

    CRB-913: Designed to be a Best-in-class Next Generation CB1 Inverse Agonist Design Goals Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs

  36. Slide 36: Oral CRB-913 is the Outcome of a Multi-year Medicinal Chemistry Campaign

    Ibipinabant (2004-2008) JD-5037 (2012-2018) / CRB-4001 (2018-2021) Completed Phase IIb (Solvay/BMS) Small, lipid soluble molecule High BBB penetration Oral Same backbone as Inversago compounds (MRI/INV family) CRB-4001 (JD5037) licensed from Jenrin in 2018 Extensive pre-IND studies carried out PK di

  37. Slide 37: CRB-913: Higher Degree of Peripheral Restriction

    CRB-913: Higher Degree of Peripheral Restriction Than Monlunabant or Rimonabant Cmax = 561 Cmax = 344 Cmax = 22 AUC = 3855 AUC = 265 Cmax Brain concentration (ng/g) Dose CRB-913 Monlunabant Rimonabant 10 mg/kg 22 344 561 1:15 1:26 1:1.6 1:15 AUC Plasma:Brain ratio Dose CRB-913 Monlunabant Rimonabant

  38. Slide 38: CRB-913: Potential Clinical Usage and supportive pre-clinical data

    1. Incretin analog therapy for insensitive/intolerant/high-risk patients 2. Combination with oral incretin agonists  potentially enhances efficacy OR improve tolerability 3. “Induction/maintenance” model: goal to potentially maintain weight loss post incretin analog therapy CRB-913: Potential Clini

  39. Slide 39: CRB-913: Dose response weight loss in DIO mice

    Source: Morningstar et al-Obesity Week 2024 CRB-913: Dose response weight loss across wide range in DIO mice Allometric scaling to humans: 30 mg/day to >450 mg/day Top weight loss observed: 38% for 80 mg/kg/day QD on day 28 Weight loss (%) by day 19 in DIO mice

  40. Slide 40: CRB-913: Enhanced Combo Effect with Semaglutide or Tirzepatide

    CRB-913: Enhanced Combo Effect with Semaglutide or Tirzepatide Source(s): Company data on file. DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 18 days of treatment (Similar effect also seen when CRB-913 was combined with liraglutide) Body weigh

  41. Slide 41: CRB-913: Induction/Maintenance with Semaglutide

    CRB-913: Induction/Maintenance with Semaglutide Source: Morningstar et al-Obesity Week 2024 “Switch” ↓ Vehicle Sema  vehicle Sema  Sema Sema  CRB-913

  42. Slide 42: Weight Loss From CRB-913 Driven By More Fat Loss Than Semaglutide

    Weight Loss From CRB-913 Driven By More Fat Loss Than Semaglutide Source: Morningstar et al-Obesity Week 2024 SemaSema SemaCRB-913 At day 41 (end of study period) Sema  Sema Sema  CRB-913 Difference Weight loss (%) -13.6 -17.1 ↑25% Fat change from baseline -3.65% -8.65% ↑x2.3 Vehicle

  43. Slide 43: Clinical Development Pathway To Determination Of Dose Response Curve

    Clinical Development Pathway To Determination Of Dose Response Curve Q4 2024 H1 2025 H2 ‘25 – H1 ‘26 H2 ‘26 – H1 ‘27 Ph1a SAD  MAD Ph1b Dose response study Phase 2 Q4 2024 2022-2023 2023-2024 2025-2026 (?) 25 mg/day 28-day (n=37) 10, 20 and 50 mg/day 16 wks (n=240) Additional dose response study (n

  44. Slide 44: Expected Milestones

    Expected Milestones Produce drug for toxicology and clinical studies Q2-2024 Complete toxicology and IND enabling studies Q4-2024 FPI SAD/MAD Q1-2025

  45. Slide 45: Leadership, Upcoming Catalysts, Financials

    Leadership Upcoming Catalysts Financials

  46. Slide 46: Management Team

    Management Team Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Christina Bertsch Head of Human Resources Accomplished senior human resource executive

  47. Slide 47: Board of Directors

    Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA. Winston Kung, MBA Director More than 20 years of senior financial, business development and investment banking experience;

  48. Slide 48: Expected Corporate Milestones

    Expected Corporate Milestones First patient dosed: Q1-2025 First patient dosed: Q4-2024 Complete Enrollment in U.S. dose escalation study: Q4-2024 Present U.S. dose escalation data: Q1-2025 CRB-701 CRB-913 CRB-601

  49. Slide 49: Investment Summary

    Investment Summary $147M Cash, cash equivalents and investments as of June 30, 2024. Approximately 11.5M Common Shares Outstanding (12.5M Fully-Diluted Shares) Nectin-4 targeting ADC for treatment of solid tumors Oral CB1R inverse agonist to treat obesity TGFβ blocker Anti-⍺vβ8 integrin mAb for trea

  50. Slide 50: Connecting Innovation to Purpose

    Connecting Innovation to Purpose NASDAQ: CRBP Corporate Presentation October 2024

  51. Slide 51: Appendix

    Appendix

  52. Slide 52: CRB-601 Potential Best-in-class avb8 mAb

    CRB-601 Potential “best-in-class” ⍺vβ8 mAb

  53. Slide 53: CRB-601 has the Potential to Enhance Checkpoint Inhibition

    CRB-601 has the Potential to Enhance Checkpoint Inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

  54. Slide 54: TGFβ predicts poor clinical outcomes in a subset of cancer patients

    TGFβ predicts poor clinical outcomes in a subset of cancer patients 0 25 20 15 10 5 0.0 0.2 0.4 0.6 0.8 1.0 N = 8,461 cancers, multiple cell types Time (years) Overall survival, % Immunogenomic subtypes in cancer Source(s): Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:817 C1 C

  55. Slide 55: Targeting the Integrin avb8 Represents a Novel Approach to Regulating TGFβ

    Targeting the Integrin ⍺vβ8 Represents a Novel Approach to Regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

  56. Slide 56: CRB-601 is Targeting Latent-TGFβ by Blocking the Integrin avb8

    CRB-601 is Targeting Latent -TGFβ by Blocking the Integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins

  57. Slide 57: mAbs targeting TGFβ activation in the clinic

    mAbs targeting TGFβ activation in the clinic Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage IND Cleared FPI Q4-2024 Phase 1/2 Phase 1 Phase 2 Phase 1 Indications Solid Tumors Soli

  58. Slide 58: CRB-601 Enhances Anti-PD-1 Therapy in Murine Tumor Models

    CRB-601 Enhances Anti-PD-1 Therapy in Checkpoint Inhibition Sensitive and Resistant Murine Tumor Models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB

  59. Slide 59: Blockade of avb8 with anti-PD-1 Increased TIL Populations in EMT6 Tumors

    Blockade of ⍺vβ8 in Combination with anti-PD-1 Increased TIL Populations in Immune Excluded EMT6 Tumors Source(s): Corbus data on file **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days

  60. Slide 60: CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors

    CRB-601 Reshapes The Landscape Of Effector T and NK Cells in MC38 Tumors Source(s): Corbus data on file

  61. Slide 61: Applying a Proprietary Algorithm To Define The Clinical Focus for CRB-601

    Applying a Proprietary Algorithm To Define The Clinical Focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):

  62. Slide 62: Patient Selection Strategies Will Enhance the Probability of Success

    Patient Selection Strategies Will Enhance the Probability of Success Source(s): Corbus proprietary analysis: Log2 fold change of Nectin-4 expression as a ratio to normal tissue Controls Ovarian Melanoma Breast Colon Prioritization of indications with differential gene expression vs. normal tissues w

  63. Slide 63: Expected Milestones

    Expected Milestones IND cleared January 2024 First patient dosed Q4-2024 Dose escalation and confirmation 1st Half of 2025

Corbus Pharmaceuticals Holdings — Investor Presentation (November 2024) on 6ix